Search Results
Your search for Matthew Stenger matches 7842 pages
Showing 7201 - 7250Patient Exhibits Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Eruptive melanocytic nevi are observed in patients receiving the multikinase inhibitor sorafenib (Nexavar) and the selective BRAF inhibitor vemurafenib (Zelboraf). In a case reported in JAMA Dermatology, Shen et al found that the addition of the MEK inhibitor cobimetinib to vemurafenib in a woman...
Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma
In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...
Major Depression Is Undertreated in Patients With Cancer
In a Scottish study reported in The Lancet Psychiatry, Walker et al assessed the prevalence and adequacy of treatment of major depression in patients with cancer of different primary sites. The prevalence of major depression ranged from 5.6% in patients with genitourinary cancers to 13.1% in those...
SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer
In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...
Integrated Collaborative Care Program Highly Successful in Treating Major Depression in Patients With Cancer
In a Scottish study (SMaRT Oncology-2) reported in The Lancet, Sharpe, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly higher depression response and remission rates...
Para-Aortic Lymph Node Radiation Increases Risk of Diabetes in Hodgkin Lymphoma Survivors
Abdominal irradiation for childhood cancer has been associated with increased risk of diabetes. In a Dutch study reported in the Journal of Clinical Oncology, van Nimwegen and colleagues assessed the relationship between infradiaphragm radiotherapy and risk of diabetes in long-term survivors of...
PIK3CA Mutations Associated With Lower Rate of Pathologic Complete Response to Neoadjuvant Anti-HER2 Therapy in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Loibl et al found that PIK3CA mutation was associated with lower pathologic complete response rate in patients with HER2-positive breast cancer receiving trastuzumab (Herceptin), lapatinib (Tykerb), or both in addition to neoadjuvant...
Male Pattern Baldness at Age 45 May Be Associated With Aggressive Prostate Cancer
In a prospective cohort study in the population of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Zhou et al found that frontal plus moderate vertex baldness at age 45 is associated with increased risk of aggressive prostate cancer. The findings were reported in the...
Primary Site of Neuroblastoma Tied to Differences in Biologic, Clinical Characteristics, Including Survival
In a study reported in Journal of Clinical Oncology, Vo et al in the International Neuroblastoma Risk Group Project found significant differences in clinical and biologic features of neuroblastoma according to primary tumor site, including poorer survival for adrenal sites of primary disease and...
Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...
Improved Survival with Adjuvant FOLFOX vs Fluorouracil/Leucovorin After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
In a Korean phase II trial reported in The Lancet Oncology, Hong et al found that adjuvant FOLFOX (oxaliplatin, fluorouracil [5-FU], leucovorin) prolonged progression-free survival and overall survival vs 5-FU/leucovorin in patients with locally advanced rectal cancer who had received neoadjuvant...
Long-Term Colorectal Cancer Mortality After Removal of Adenomas
There are few data available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Løberg et al found that patients who had low-risk adenomas removed had lower colorectal cancer mortality risk and those...
Adding Cediranib to Olaparib Improves Progression-Free Survival and Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer
In a randomized phase II trial reported in The Lancet Oncology, Liu et al found a significant improvement in progression-free survival and an increase in toxicity with the addition of the antiangiogenic agent cediranib (VEGFR-1,-2,-3 inhibitor) to the PARP inhibitor olaparib in women with recurrent ...
Baseline Results of the UK Phase III ProtecT Trial of Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localized Prostate Cancer
The UK phase III ProtecT trial is comparing the effectiveness of active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. Lane et al have provided baseline results of the trial in an article in The Lancet Oncology. Study Details In the trial, men aged 50...
Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies
In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...
Little Molecular Difference and No Prognostic Effect of Clinical HER2 Status in Context of Intrinsic Breast Cancer Subtypes
In a study reported in the Journal of the National Cancer Institute, Prat et al found that there was little difference in downstream gene or protein expression according to intrinsic breast cancer subtypes among clinical HER2-positive vs -negative breast cancers and that clinical HER2 status did...
No Significant Progression-Free Survival Benefit of Adding Ramucirumab to First-Line Docetaxel in Advanced HER2-Negative Breast Cancer
In the phase III ROSE/TRIO-12 trial, reported in the Journal of Clinical Oncology, Mackey et al found no significant improvement in investigator-assessed progression-free survival by adding the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to first-line docetaxel in women with...
Increased Risk of Melanoma in Flight-Based Occupations
Airline pilots and cabin crew are occupationally exposed to higher levels of cosmic and ultraviolet radiation. In a meta-analysis reported in JAMA Dermatology, Sanlorenzo et al found that these people have a more than twofold greater risk of melanoma compared with the general population. Increased ...
Modeling Study Critical of Intensive Colonoscopy Screening in Medicare Population
A modeling study reported in JAMA Internal Medicine by van Hees and colleagues showed that colonoscopy screening at intervals shorter than 10 years or continuing past 75 years of age in the Medicare population is associated with a reduced net health benefit from a societal perspective. Study ...
Modeling Study Indicates Little Survival Difference With Contralateral Prophylactic Mastectomy in Breast Cancer Without BRCA Mutation
In a study reported in the Journal of the National Cancer Institute, Portschy et al found an absolute 20-year overall survival difference of < 1% with contralateral prophylactic mastectomy in women with stage I or II breast cancer without BRCA mutation. The authors had hypothesized that the...
Racial/Ethnic Barriers to Breast Reconstruction After Mastectomy for Breast Cancer
In a study reported in JAMA Surgery, Morrow et al found that breast reconstruction after mastectomy for breast cancer largely reflects patient demand, with the majority of women being satisfied with the decision-making process. However, black women were significantly less likely to have...
Baseline Vitamin D Not Associated With Survival in Patients With Advanced Pancreatic Cancer in CALGB 80303/Alliance Trial
Preclinical data indicate a role of vitamin D metabolism in pancreatic tumor development. In a study reported in the Journal of the National Cancer Institute, Van Loon et al found that baseline serum 25-hydroxyvitamin D (25[OH]D) levels were not associated with progression-free survival or overall...
No Benefit of Adding Cetuximab to Cisplatin and Accelerated Radiotherapy in Stage III or IV Head and Neck Carcinoma
Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in...
ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
Less Frequent Use of Sentinel Lymph Node Biopsy and Higher Risk of Lymphedema in Black Women With Breast Cancer in Medicare Population
In a retrospective study reported in JAMA Surgery, Black et al found that the sentinel lymph node biopsy rate was lower and risk for lymphedema higher in black vs white women with early-stage breast cancer in the Medicare population. Study Details The study used the Surveillance, Epidemiology,...
No Significant Difference in Time to Treatment Failure With Rituximab Retreatment vs Maintenance in Low-Tumor-Burden Follicular Lymphoma
Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...
ASCO Issues New Guideline on Chemotherapy and Targeted Therapy in Advanced HER2-Negative or Unknown HER2 Status Breast Cancer
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or unknown HER2 status breast cancer. The guideline is published in the Journal of Clinical Oncology. In formulating the consensus...
No Benefit of Adding Cilengitide in Glioblastoma With Methylated MGMT Promoter
In the phase III CENTRIC EORTC 26071-22072 trial reported in The Lancet Oncology, Stupp et al found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard temozolomide chemoradiotherapy produced no survival benefit in newly diagnosed glioblastoma...
Melanoma With High Mitotic Rate Is Associated With Aggressive Histologic Features and Atypical Presentation
High mitotic rate in primary melanomas appears to be an independent predictor of poorer survival. In a single-institution study reported in JAMA Dermatology, Shen et al found that high mitotic rate primary melanoma is associated with male sex, older age, amelanosis, and several aggressive...
Adding Lenalidomide to R-CHOP Appears to Overcome Negative Prognostic Impact of the Non-Germinal Center B-Cell Phenotype in DLBCL
A phase II study reported in the Journal of Clinical Oncology by Nowakowski et al indicates that the addition of lenalidomide (Revlimid) to R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone)—a regimen known as R2CHOP—overcomes the negative...
Small but Statistically Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC
In the phase III REVEL trial reported in The Lancet, Garon et al found that the addition of the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to docetaxel produced a statistically significant improvement in overall survival as second-line treatment in patients with non–small...
Differences in Radiotherapy Coverage in the ACOSOG Z0011/Alliance Trial in Breast Cancer
The ACOSOG Z0011/Alliance trial showed that axillary lymph node dissection provides no benefit over sentinel lymph node biopsy in patients with breast cancer with one or two positive sentinel lymph nodes undergoing lumpectomy, radiotherapy, and systemic therapy. In an analysis reported in the...
Vitamin D Deficiency Worsens Response to Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Bittenbring et al found that vitamin D deficiency was associated with poorer outcome in older patients receiving R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma...
Better Survival, but Narrowing Gap, With Surgical vs Nonsurgical Treatment of Advanced Laryngeal Cancer
Although chemoradiation has been increasingly used in advanced laryngeal cancer as part of an organ-preservation strategy, there is concern that this practice may have contributed to a decline in survival suggested by some data in this setting. In a population-based cohort study reported in JAMA...
Inclusion of Endogenous Hormone Levels Improves Risk Prediction for Postmenopausal Breast Cancer
In a study reported in the Journal of Clinical Oncology, Tworoger et al found that inclusion of endogenous hormone levels in the Gail and Rosner-Colditz risk scores improved prediction of postmenopausal invasive breast cancer. Study Details The study involved 437 patients with breast cancer and...
Promising Activity of Ibrutinib Plus Rituximab in High-Risk CLL
In a phase II trial reported in The Lancet Oncology, Burger et al found that the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) showed promising activity and an encouraging safety profile in patients with previously treated or untreated high-risk chronic lymphocytic leukemia (CLL)....
Brentuximab Vedotin Shows First-Line Activity in Phase I Study in CD30-Positive Peripheral T-Cell Lymphoma
In a phase I study reported in the Journal of Clinical Oncology, Fanale et al found that brentuximab vedotin (Adcetris)—a conjugate of antibody specific for CD30 and a microtubule-disrupting chemotherapy agent—exhibited high activity when combined sequentially with CHOP...
No Mortality Differences With Intermediate- or Short-Term Androgen Suppression With or Without Zoledronic Acid in Locally Advanced Prostate Cancer
In a phase III Australian/New Zealand trial (TROG 03.04 RADAR) reported in The Lancet Oncology, Denham et al found no differences in prostate cancer–specific or all-cause mortality with intermediate-term androgen suppression and radiotherapy or short-term suppression plus radiotherapy with or ...
Active Surveillance for Clinical Stage I Testicular Cancer Associated With ‘Excellent’ Outcomes
In a retrospective study reported in the Journal of Clinical Oncology, Kollmannsberger et al found that active surveillance for patients with clinical stage I testicular cancer is associated with very good outcomes. Most relapses occurred within 2 years of orchiectomy in patients with nonseminoma...
Accuracy of Edinburgh Ovarian Tissue Cryopreservation Criteria in Girls and Young Women With Cancer
A study reported in The Lancet Oncology by Wallace et al evaluated the accuracy of criteria used for predicting ovarian insufficiency and offering ovarian tissue cryopreservation in young women with cancer at the Edinburgh Children’s Cancer Centre. Ovarian tissue cryopreservation with later...
Increasing Incidence of Merkel Cell Carcinoma in Queensland, Australia
In a study reported in JAMA Dermatology, Youlden et al found that the incidence of Merkel cell carcinoma in Queensland, Australia, a known high-risk area, increased by 2.6% annually between 1993 and 2010. Five-year relative survival was 41%, with significantly better survival found in patients aged ...
Single-Institution Study Shows No Correlation of Primary Melanoma Regression With Sentinel Node Status
In a single-institution study reported in JAMA Dermatology, Botella-Estrada et al found that regression of primary melanomas is not associated with sentinel node status. Study Details The retrospective study involved patients with melanomas with Breslow thickness > 0.75 mm undergoing sentinel...
Neoadjuvant Chemotherapy Reduces Postoperative Morbidity in Women With Breast Cancer Undergoing Mastectomy
In a study reported in JAMA Surgery, Abt et al found that neoadjuvant chemotherapy is safe in women with breast cancer undergoing mastectomy with or without immediate breast reconstruction. Neoadjuvant chemotherapy was an independent predictor of reduced 30-day postoperative morbidity in women...
Low Incidence of Colorectal Cancer, Elevated Rate of Postprocedure Hospitalization in Elderly Patients Undergoing Surveillance Colonoscopy
In a retrospective cohort study reported in JAMA Internal Medicine, Tran et al found a low rate of colorectal cancer and a relatively high rate of postprocedure hospitalization in elderly patients undergoing surveillance colonoscopy. Study Details The study involved patients aged ≥ 50 years...
Poorer Psychosexual Functioning in Adult Female Survivors of Childhood Cancer
In an analysis in the Childhood Cancer Survivor Study population reported in the Journal of Clinical Oncology, Ford et al found that adult woman survivors of childhood cancer have poorer psychosexual function than their siblings without childhood cancer. Risk factors for poorer function included...
Updated Recommendations for Evaluation, Staging, and Response Assessment for Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Updated recommendations (the Lugano Classification) for initial evaluation, staging, and assessment of response in patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have been presented in the Journal of Clinical Oncology by Cheson et al. The recommendations are the result of two...
ICML Imaging Working Group Issues Updated Guidelines on PET-CT for Staging and Response Assessment for FDG-Avid Lymphomas
Barrington et al in the International Conference on Malignant Lymphomas Imaging Working Group have presented updated consensus guidelines on 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-computed tomography (CT) for staging and response assessment for FDG-avid lymphomas. The...
Analysis of Randomized Bisphosphonate Osteoporosis Trials Indicates No Reduction in Risk of Postmenopausal Breast Cancer
Observational studies have suggested a potential effect of bisphosphonate treatment for osteoporosis in reducing risk of breast cancer in postmenopausal women. However, an analysis of the randomized FIT trial of alendronate and HORIZON-PFT trial of zoledronic acid reported in JAMA Internal Medicine ...
Body Mass Index Positively Associated With Many Cancers in UK Study
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
Proposed Modification Incorporating Depth of Invasion in Primary Staging for Oral Cancer
In an analysis reported in JAMA Otolaryngology-Head & Neck Surgery, the International Consortium for Outcome Research (ICOR) in Head and Neck Cancer proposed modifying the current American Joint Committee on Cancer (AJCC) staging system for oral cancer to include depth of invasion. A model...
